Blog
RSS FeedPosted by Michael Wonder on 01 Dec 2022
Afraid of pharma pushback, a health data broker puts up a barrier to drug pricing information
1 December 2022 - At a time when many Americans are clamouring for more transparency into prescription drug pricing, one ...
Posted by Michael Wonder on 30 Nov 2022
How CSL priced the world’s most expensive drug
1 December 2022 - When blood products giant CSL announced last week it had been given US regulatory approval for ...
Posted by Michael Wonder on 24 Nov 2022
Korea to add Canada, Australia to drug pricing reference country list
24 November 2022 - The Government said it would additionally reference Canada and Australia when setting drug prices from January ...
Posted by Michael Wonder on 21 Nov 2022
Bristol Myers Squibb warns US price reforms will dent drug development
20 November 2022 - Biggest shake-up in pharma pricing in decades prompts companies to shelve some potential therapies. ...
Posted by Michael Wonder on 21 Nov 2022
Big pharma may have to reveal government deals in WHO's draft pandemic rules
17 November 2022 - Pharmaceutical companies could be made to disclose prices and deals agreed for any products they make ...
Posted by Michael Wonder on 21 Nov 2022
Getting the price right: lessons for Medicare price negotiation from peer countries
9 November 2022 - The US pays more for brand-name prescription drugs than any other country and new legislation from August ...
Posted by Michael Wonder on 19 Nov 2022
Inflation Reduction Act drug pricing provisions aren’t at all like price controls in Europe
18 November 2022 - The opposition to the prescription drug pricing provisions in the Inflation Reduction Act can be hyperbolic. ...
Posted by Michael Wonder on 17 Nov 2022
A tussle over medicines pricing is looming in Britain
15 November 2022 - Agreement to limit the size of the NHS drugs bill under strain. ...
Posted by Michael Wonder on 11 Nov 2022
EQRx no longer seeks to disrupt prices in non-small-cell lung cancer space
10 November 2022 - The biotechnology company EQRx no longer seeks to disrupt prices in the non-small-cell lung cancer space. ...
Posted by Michael Wonder on 11 Nov 2022
Implementation of the Patented Medicine Prices Review Board's proposed Guidelines will harm Canadian patients
10 November 2022 - Innovative Medicines Canada is calling on Health Canada to direct the Patented Medicine Prices Review Board (PMPRB) ...
Posted by Michael Wonder on 07 Nov 2022
New PMPRB guidelines proposed for assessing prices of patented medicines sold in Canada
4 November 2022 - Controversial amendments to the Patented Medicines Regulations changing the basket of comparator countries considered by the ...
Posted by Michael Wonder on 03 Nov 2022
New US cancer drug prices rise 53% in five years
2 November 2022 - The annual price of a newly-launched cancer drug in the United States averaged $283,000 last year, ...
Posted by Michael Wonder on 01 Nov 2022
Association between US drug price and measures of efficacy for oncology drugs approved by the US FDA from 2015 to 2020
31 October 2022 - The past five years have seen a marked increase in the number of cancer therapies on the ...
Posted by Michael Wonder on 30 Oct 2022
Another example of a “Shkrelian” drug price increase
28 October 2022 - The story of Martin Shkreli and the drug, Daraprim, has been used as an example of drug ...
Posted by Michael Wonder on 27 Oct 2022
Drug maker raises the price of an old chemo medicine tenfold amid persistent shortages
27 October 2022 - Amid sporadic shortages of a drug that is essential in preparing patients for lifesaving, cancer-fighting treatments, ...